Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Non-Small-Cell Lung × tislelizumab × Clear all

Phase

Status

Recruiting 18 Not yet recruiting 9 Active not recruiting 9 Completed 6 Unknown 5 Terminated 4 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Mesothelioma, Malignant 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Anus Neoplasms 1

Interventions

Carboplatin 24 Cisplatin 19 Pemetrexed 18 Docetaxel 15 Radiotherapy 13 Paclitaxel 13 Gemcitabine 13 Nivolumab 12 Radiosurgery 11 pembrolizumab 10 durvalumab 10 Erlotinib Hydrochloride 8 atezolizumab 6 Taxes 6 Magnetic Resonance Spectroscopy 6 Cyclophosphamide 6 Gefitinib 5 Drug Therapy 5 Bevacizumab 5 Platinum 4 130-nm albumin-bound paclitaxel 4 sotorasib 3 Surveys and Questionnaires 3 Sirolimus 3 Ramucirumab 3 Polymerase Chain Reaction 3 Immunotherapy 3 Fulvestrant 3 Fluorodeoxyglucose F18 3 Etoposide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05791097 2023-07-24

AdvanTIG-306

Novartis

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡